A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

April 30, 2005

Conditions
Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated
Interventions
DRUG

Zoledronic acid

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY